AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Calling All Derms! Chronic Spontaneous Urticaria Is For You!

Description

Madam Friedman, the chairman director at GW, delivered a presentation on the management of Chronic Spontaneous Urticaria (CSU), emphasizing its prevalence, complex pathophysiology, and the urgency for dermatologists to engage with this condition. CSU affects approximately 3-5% of the global population, yet it has often been overlooked in drug development. The talk highlighted the necessity for a robust management strategy, including the adoption of current guidelines, with contrasting approaches from Europe and the U.S. The European guideline advocates for rapid therapeutic escalation, allowing for up to four times the standard dosage of antihistamines within weeks, while U.S. practices tend to be more conservative. Diagnosis hinges on identifying transient urticarial plaques and encouraging patients to document their symptoms visually. Effective treatment strategies encompass the use of second-generation antihistamines and advanced therapies, such as omalizumab, with new drugs anticipated for early approval. The speaker stressed the importance of combining therapies rather than replacing them when treatments fail. Furthermore, plans to personalize patient treatment and consider comorbidities were discussed, alongside the need for a fast-tracked therapeutic approach to improve patient quality of life. The presentation concluded with optimism for future drug developments that could enhance treatment options for CSU.

View more

Conclusions

  • Chronic spontaneous urticaria (CSU) affects a significant portion of the global population, yet remains under-researched and has limited treatment options.
  • A substantial percentage of CSU patients experience a resolution of symptoms over time, but many continue to suffer from chronic symptoms that significantly impact their quality of life.
  • Understanding the complex pathophysiology of CSU is essential for effective management, indicating multiple pathways and mediators are involved.
  • Current treatment guidelines differ between Europe and the U.S., with European guidelines advocating for more aggressive uptitration of antihistamines to achieve quicker symptom control.
  • Omalizumab is an effective treatment option for CSU, but many patients still experience inadequate response rates.
  • Emerging therapies and a better understanding of CSU's mechanisms may help alleviate the unmet clinical needs in the management of this condition.
  • Combination therapy is often necessary, as patients may not respond effectively to mono-therapy or standard dosing alone.
  • A proactive approach to management that includes early identification of potential triggers and frequent follow-up can improve patient outcomes.
  • Immunol Allergy Clin North Am. 2014;34:33-52.
  • Allergy. 2011;66:317-330.
  • Clin Rev Allergy Immunol. 2002;23:147-169.
  • Nat Rev Dis Primers. 2022;8(1):61.
  • J Allergy Clin Immunol. 2017;139:1772-1781.
  • J Allergy Clin Immunol Pract. 2018;6:1097-1106.
  • J Allergy Clin Immunol. 2019;144:353-360.
  • J Allergy Clin Immunol. 2017;140(6):1726-1728.
  • Zuberbier T et al. Allergy. 2022;77:734-766.
  • Ann Allergy Asthma Immunol. 2000;85(6 Pt 2):532-544.
  • Clinics in Dermatology (2014) 32, 420-423.
  • Bernstein JA, et al. J Allergy Clin Immunol. 2014 May;133(5):1270-7.
  • Kaplan AP et al: J Allergy Clin Immunol 2008; 122:569.
  • Magerl M et al: J Allergy Clin Immunol 2010;126:665.
  • Di Gioacchino M et al: Allergy Asthma Proc 2003; 24: 285.
  • Baskan EB et al .Dermatolog Treat. 2004; 15(3):164-8.
  • Toubi E et al: Allergy 1997; 52: 312.
  • Kessel A et al. Allergy 2010; 65:1478.
  • Vena GA et al. J Am Acad Dermatol. 2006;55(4):705-9.
  • Shahar E et al. International Journal of Dermatology, 45: 1224-1227.
  • Zimmeran AB et al. J Am Acad Dermatol. 2012; 66(5):767-70.
  • Berroeta L et al: Clin Exp Dermatol 2004; 29: 97.
  • Aydogan, K. et al. International Journal of Dermatology, 51: 98-103.
  • Engen B et al. Acta Derm Venereol 2008; 88: 247-251.
  • Cassano N et al: Acta Derm Venereol 2005; 85: 254.
  • Engin B, Ezdemir O. J Eur Acad Dermatol Venereol 2008; 22: 481.